1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2016

Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 115 pages

Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2016’, provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Secondary Progressive Multiple Sclerosis (SPMS)
- The report reviews pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Secondary Progressive Multiple Sclerosis (SPMS) therapeutics and enlists all their major and minor projects
- The report assesses Secondary Progressive Multiple Sclerosis (SPMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Secondary Progressive Multiple Sclerosis (SPMS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Secondary Progressive Multiple Sclerosis (SPMS) Overview 9
Therapeutics Development 10
Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS) - Overview 10
Secondary Progressive Multiple Sclerosis (SPMS) - Therapeutics under Development by Companies 11
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Secondary Progressive Multiple Sclerosis (SPMS) - Products under Development by Companies 16
Secondary Progressive Multiple Sclerosis (SPMS) - Companies Involved in Therapeutics Development 17
AB Science SA 17
Actelion Ltd 18
Biogen, Inc. 19
Daval International Limited 20
Genzyme Corporation 21
Immune Response BioPharma, Inc. 22
Innate Immunotherapeutics Ltd 23
Kyorin Pharmaceutical Co., Ltd. 24
Mallinckrodt Plc 25
MedDay 26
MedImmune, LLC 27
Merck KGaA 28
Novartis AG 29
Opexa Therapeutics, Inc. 30
Xenetic Biosciences (UK) Limited 31
Secondary Progressive Multiple Sclerosis (SPMS) - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
Aimspro - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
ApE - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
biotin - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
DC-TAB - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
GZ-402668 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
ibudilast - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
imilecleucel-t - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
inebilizumab - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
interferon beta-1b - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
IR-902 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
M-2736 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
masitinib - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
methoxsalen - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
MIS-416 - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
MyeloXen - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
opicinumab - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
OSX-110 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
ponesimod - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
siponimod - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
Secondary Progressive Multiple Sclerosis (SPMS) - Recent Pipeline Updates 79
Secondary Progressive Multiple Sclerosis (SPMS) - Dormant Projects 105
Secondary Progressive Multiple Sclerosis (SPMS) - Discontinued Products 106
Secondary Progressive Multiple Sclerosis (SPMS) - Product Development Milestones 107
Featured News and Press Releases 107
Dec 01, 2015: MedDay provides update on MS-ON study of MD-1003 107
Oct 06, 2015: Opexa Announces Granting of New T-cell Patents Covering Tcelna; Patent Estate Increases to 160 Issued Patents 108
Aug 06, 2015: Medical Need Europe appoints Durbin as latest distribution partner 108
Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting 109
Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC 109
Oct 07, 2014: Update on Innate's Phase 2B trial and other recent activities 110
Aug 19, 2014: Innate's Phase 2B clinical trial on SPMS to start recruiting patients following Perth site obtaining ethics approval 110
Jun 20, 2014: Update on Phase 2B Trial of MIS416 in Patients with Secondary Progressive Multiple Sclerosis 111
Jun 18, 2014: Compassionate Use Programme Update 111
May 13, 2014: Opexa Reaches Enrollment Target in Phase IIb Trial of Personalized Immunotherapy for Secondary Progressive Multiple Sclerosis 112
Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 114
Disclaimer 115

List of Tables
Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H1 2016 10
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by AB Science SA, H1 2016 17
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Actelion Ltd, H1 2016 18
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Biogen, Inc., H1 2016 19
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Daval International Limited, H1 2016 20
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Genzyme Corporation, H1 2016 21
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Immune Response BioPharma, Inc., H1 2016 22
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Innate Immunotherapeutics Ltd, H1 2016 23
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 24
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Mallinckrodt Plc, H1 2016 25
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by MedDay, H1 2016 26
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by MedImmune, LLC, H1 2016 27
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Merck KGaA, H1 2016 28
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Novartis AG, H1 2016 29
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Opexa Therapeutics, Inc., H1 2016 30
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Xenetic Biosciences (UK) Limited, H1 2016 31
Assessment by Monotherapy Products, H1 2016 32
Number of Products by Stage and Target, H1 2016 34
Number of Products by Stage and Mechanism of Action, H1 2016 36
Number of Products by Stage and Route of Administration, H1 2016 38
Number of Products by Stage and Molecule Type, H1 2016 40
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics - Recent Pipeline Updates, H1 2016 79
Secondary Progressive Multiple Sclerosis (SPMS) - Dormant Projects, H1 2016 105
Secondary Progressive Multiple Sclerosis (SPMS) - Discontinued Products, H1 2016 106

List of Figures
Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 14
Assessment by Monotherapy Products, H1 2016 32
Number of Products by Top 10 Targets, H1 2016 33
Number of Products by Stage and Top 10 Targets, H1 2016 33
Number of Products by Top 10 Mechanism of Actions, H1 2016 35
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 35
Number of Products by Routes of Administration, H1 2016 37
Number of Products by Stage and Routes of Administration, H1 2016 37
Number of Products by Molecule Types, H1 2016 39
Number of Products by Stage and Molecule Types, H1 2016 39

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Nuclear Factor Erythroid 2 Related ...

Dystrophin (DMD) - Pipeline Review, H2 2016

Dystrophin (DMD) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Dystrophin (DMD) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Dystrophin (DMD) - Pipeline Review, H2 2016’, provides in depth analysis on Dystrophin (DMD) targeted pipeline therapeutics. ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.